Compare Novo Nordisk A/S (NVO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares UltraPro Short QQQ ETF — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while ProShares UltraPro Short QQQ ETF trades at $38.76. The key difference: Novo Nordisk A/S pays a 3.98% dividend while ProShares UltraPro Short QQQ ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SQQQ | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $89.43 |
52-Week Low | $35.29 | $36.04 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are predominantly bearish, with moving averages signaling sell and oscillators neutral. The ETF is designed to gain when the Nasdaq-100 declines, but its structure leads to value erosion over time due to daily resets. Recent news highlights its use as a tactical hedge amid tech sector volatility but warns of long-term unsuitability.
The outlook for SQQQ is highly speculative and short-term oriented. It may offer tactical gains if tech stocks weaken, but structural decay and high volatility pose significant risks. Investors should view it as a hedging tool rather than a long-term holding, with success dependent on precise market timing and active management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
